Who is sponsoring NCT04422470?

NCT04422470 is sponsored by National Research Center for Hematology, Russia.

What drugs are being tested in NCT04422470?

Interventions in NCT04422470: Non-interventional study.

What condition does NCT04422470 study?

NCT04422470 studies Coronavirus Infection and Hematologic Diseases.

Is NCT04422470 still recruiting?

NCT04422470 is currently completed. Last updated 26 January 2023.

Last reviewed 2023-01-26 · How we verify

NCT04422470: CHRONOS19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Registry of Patients With Hematologic Disease and COVID-19 in Russia

Completed Last updated 26 January 2023

What this trial tests

trial testing Non-interventional study in Coronavirus Infection and Hematologic Diseases in 666 participants. Completed in 18 January 2022.

Timeline

22 June 2020

Primary endpoint
22 August 2021

18 January 2022

Quick facts

Lead sponsor	National Research Center for Hematology, Russia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	666
Start date	22 June 2020
Primary completion	22 August 2021
Estimated completion	18 January 2022
Sites	15 locations across Russia

Drugs / interventions tested

Non-interventional study (non-interventional-study) — full drug profile →

Conditions studied

Coronavirus Infection and Hematologic Diseases — all drugs for Coronavirus Infection and Hematologic Diseases →

Sponsor

National Research Center for Hematology, Russia — full company profile →

Who can join

18 and older, any sex, with Coronavirus Infection and Hematologic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Aleshina OA, Zakurdaeva K, Vasileva AN, Dubov SK, et al · · 2023 · cited 4× · PMID 37236904 · DOI 10.1016/j.clml.2023.04.002
1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
Zakurdaeva K, Gavrilina O, Vasileva A, Dubov S, et al · · 2021

Verify or expand the search:

Other trials of Non-interventional study

Trials testing the same drug.

NCT06102993 — Ferroptosis in Patients With COPD COPD With/Without Risk of Cardiovascular Events. Pathophysiological Implications, Diag · unknown
NCT06555965 — STXBP1 and SYNGAP1 Related Disorders Natural History Study · recruiting
NCT05908682 — Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes · recruiting
NCT07157436 — Implementation of Point Of Care UltraSound in the Assessment of Crohn's Disease -The POCUS Study · terminated
NCT04495530 — Information Needs Around Parenteral nUTrition in Cancer · completed

Other National Research Center for Hematology, Russia trials

Trials by the same sponsor.

NCT06721598 — An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproli · not yet recruiting
NCT06705530 — A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphop · Phase 1, PHASE2 · completed
NCT06237192 — MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients · NA · recruiting
NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
NCT05158608 — Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04422470 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Research Center for Hematology, Russia
Last refreshed: 26 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04422470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing